Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar import2udirect (< 20) Submitted: 7/28/2012 6:31:10 AM : Outperform Start Price: $6.78 EXEL Score: -52.24

recently heard of a cancer drug that singled out white blood cells in aids and gave the hiv aids one huge leap in finding a cure interesting how that works trying to cure cancer and whola cure hiv instead maybe we should focus on hiv so we can cure cancer thats the interesting thing about research you never know what your going to find out next or cure

Featured Broker Partners


Advertisement